Identification of class ii HLA alloantibodies in placenta‐eluted gamma globulins used for treating rheumatoid arthritis

Open Access
Publisher Website
Google Scholar
Abstract
Placenta-eluted gamma globulins (PEGG) have been recently and successfully used in the treatment of patients with rheumatoid arthritis. PEGG, eluted at acid pH from large pools of human placentas, contained 99% IgG material. Sephacryl S300 gel filtration revealed a main fraction (76%) of native IgG accompanied by 10% aggregates and 14% digested fragments (as identified by sodium dodecyl sulfate—polyacrylamide gel electrophoresis and immunoelectrophoresis with specific antisera). Previous in vitro data had suggested that alloantibodies to class II HLA antigens were present in this preparation. This study confirms that PEGG and F(ab')2 fragments were able to inhibit stimulating cells in mixed lymphocyte reactions. Additional findings showed that: (a) IgG from PEGG were cytotoxic for the non—T cell population; (b) IgG or F(ab')2 from PEGG bound only to class II HLA—bearing cells; (c) F(ab')2 from PEGG were able to block the complement-mediated cytotoxicity of anti—HLA—DR and anti-DQw1 alloantibodies. These data confirm the presence of class II HLA alloantibodies in PEGG. These antibodies may account for the clinical improvement reported in patients with rheumatoid arthritis. Our findings are similar to recent data showing that the injection of anti-Ia antibodies in experimental animal models decreases the autoimmune process.